| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Incidence of port-site hernias after robot-assisted radical prostatectomy with the fascial closure of only the midline 12-mm port site.
|
J Endourol
|
2012
|
1.67
|
|
2
|
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.
|
Urology
|
2013
|
1.63
|
|
3
|
Use of a hyaluronic acid-carboxymethylcellulose adhesion barrier on the neurovascular bundle and prostatic bed to facilitate earlier recovery of erectile function after robot-assisted prostatectomy: an initial experience.
|
J Endourol
|
2013
|
1.39
|
|
4
|
EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
|
Clin Cancer Res
|
2011
|
1.33
|
|
5
|
A four-gene signature predicts disease progression in muscle invasive bladder cancer.
|
Mol Med
|
2011
|
1.14
|
|
6
|
Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
|
Oncotarget
|
2014
|
1.13
|
|
7
|
Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer.
|
Int J Oncol
|
2012
|
1.12
|
|
8
|
HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling.
|
Int J Cancer
|
2013
|
1.11
|
|
9
|
Functional and oncologic outcomes comparing interfascial and intrafascial nerve sparing in robot-assisted laparoscopic radical prostatectomies.
|
J Endourol
|
2009
|
1.06
|
|
10
|
The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding of the Smad complex to its target sequence.
|
J Biol Chem
|
2002
|
1.05
|
|
11
|
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells.
|
J Biol Chem
|
2002
|
0.97
|
|
12
|
Effect of bone morphogenetic protein-6 on macrophages.
|
Immunology
|
2008
|
0.95
|
|
13
|
Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line.
|
Cancer Res
|
2007
|
0.93
|
|
14
|
Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels.
|
J Korean Med Sci
|
2011
|
0.92
|
|
15
|
BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages.
|
Cancer Res
|
2013
|
0.90
|
|
16
|
Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways.
|
J Biol Chem
|
2010
|
0.90
|
|
17
|
Clavien classification of complications after the initial series of robot-assisted radical prostatectomy: the Cancer Institute of New Jersey/Robert Wood Johnson Medical School experience.
|
J Endourol
|
2010
|
0.89
|
|
18
|
Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.
|
Prostate
|
2013
|
0.86
|
|
19
|
Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
|
Clin Genitourin Cancer
|
2012
|
0.85
|
|
20
|
Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.
|
Asian J Androl
|
2011
|
0.84
|
|
21
|
Korean prostate cancer patients have worse disease characteristics than their American counterparts.
|
Asian Pac J Cancer Prev
|
2013
|
0.84
|
|
22
|
Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.84
|
|
23
|
Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
|
Ann Surg Oncol
|
2014
|
0.84
|
|
24
|
Clinical Significance of Wnt/β-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer.
|
World J Mens Health
|
2013
|
0.84
|
|
25
|
Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer.
|
PLoS One
|
2010
|
0.83
|
|
26
|
Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop.
|
Prostate
|
2011
|
0.83
|
|
27
|
Pathologic implications of prostatic anterior fat pad.
|
Urol Oncol
|
2011
|
0.83
|
|
28
|
Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
|
Urol Int
|
2013
|
0.82
|
|
29
|
GSTM1 tissue genotype as a recurrence predictor in non-muscle invasive bladder cancer.
|
J Korean Med Sci
|
2011
|
0.81
|
|
30
|
RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
|
J Surg Oncol
|
2011
|
0.81
|
|
31
|
Comprehensive analysis of sexual function outcome in prostate cancer patients after robot-assisted radical prostatectomy.
|
J Endourol
|
2013
|
0.81
|
|
32
|
CREBZF, a novel Smad8-binding protein.
|
Mol Cell Biochem
|
2012
|
0.81
|
|
33
|
Tissue hOGG1 genotype predicts bladder cancer prognosis: a novel approach using a peptide nucleic acid clamping method.
|
Ann Surg Oncol
|
2010
|
0.81
|
|
34
|
DHCR24 is an independent predictor of progression in patients with non-muscle-invasive urothelial carcinoma, and its functional role is involved in the aggressive properties of urothelial carcinoma cells.
|
Ann Surg Oncol
|
2014
|
0.81
|
|
35
|
Mechanism of pro-tumorigenic effect of BMP-6: neovascularization involving tumor-associated macrophages and IL-1a.
|
Prostate
|
2014
|
0.80
|
|
36
|
HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
|
J Urol
|
2010
|
0.80
|
|
37
|
Bone morphogenetic protein 6-induced interleukin-1β expression in macrophages requires PU.1/Smad1 interaction.
|
Mol Immunol
|
2011
|
0.80
|
|
38
|
Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells.
|
J Urol
|
2008
|
0.79
|
|
39
|
Renal hilar control during laparoscopic partial nephrectomy: to clamp or not to clamp.
|
J Endourol
|
2010
|
0.79
|
|
40
|
Tumorigenic and prognostic significance of RASSF1A expression in low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer.
|
Urology
|
2012
|
0.79
|
|
41
|
Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia.
|
Prostate
|
2011
|
0.79
|
|
42
|
Impact of robot-assisted radical prostatectomy on lower urinary tract symptoms and predictive factors for symptom changes: a longitudinal study.
|
Urology
|
2013
|
0.78
|
|
43
|
Independent predictors of recovery of continence 3 months after robot-assisted laparoscopic radical prostatectomy.
|
J Endourol
|
2012
|
0.78
|
|
44
|
Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma.
|
World J Surg Oncol
|
2014
|
0.78
|
|
45
|
Three-gene signature predicts disease progression of non-muscle invasive bladder cancer.
|
Oncol Lett
|
2011
|
0.78
|
|
46
|
Laparoscopic partial nephrectomy without hilar control.
|
J Endourol
|
2008
|
0.78
|
|
47
|
Bone morphogenetic protein signaling: implications in urology.
|
Korean J Urol
|
2010
|
0.77
|
|
48
|
Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.
|
Korean J Urol
|
2013
|
0.77
|
|
49
|
Downregulation of fumarate hydratase is related to tumorigenesis in sporadic renal cell cancer.
|
Urol Int
|
2012
|
0.76
|
|
50
|
Editorial comment for Rebuck et al.
|
J Endourol
|
2011
|
0.75
|
|
51
|
Diagnostic role of prostate resection in the elderly patients who experience significant co-morbidity with a high clinical suspicion of prostate cancer.
|
J Korean Med Sci
|
2013
|
0.75
|
|
52
|
Editorial comment.
|
Urology
|
2013
|
0.75
|
|
53
|
Impact of robot-assisted radical prostatectomy on health-related quality of life in patients with lower urinary tract symptoms.
|
Int J Urol
|
2011
|
0.75
|
|
54
|
Enzalutamide: looking back at its preclinical discovery.
|
Expert Opin Drug Discov
|
2014
|
0.75
|